Our study demonstrates that the combination of CD16-positive NK cells (haNK and primary NK cells) and the fully humanized anti-CD123 mAb CSL362 is highly active against CD123-expressing HL. The gene discussed is IL3RA; the disease is Hodgkins lymphoma.